AASM 2026 Position Direction on Nasal Stents: What the Evidence Now Suggests
An honest analysis of how AASM-style sleep medicine guidance is evolving for nasal stents in 2026, what it means for patients, and where it still falls short.
Why AASM Direction on Nasal Stents Matters
The American Academy of Sleep Medicine sets the pace for OSA care across North America and influences guidelines worldwide. When AASM-aligned evidence reviews shift their language on a therapy, insurance, primary care, and patient adoption follow within a few years. This article reviews how the cumulative 2024-2026 literature and AASM-style appraisal are evolving for nasal stents, including how this affects choices around the Back2Sleep nasal stent.
We will be transparent: this is an analysis of evolving evidence-based guidance, not a verbatim citation of a single 2026 official position statement. The direction is clear from cumulative data, but readers and clinicians should always check the AASM website for the latest formal documents before treatment decisions. Pair this with our broader review of CPAP alternatives in 2026.
From AASM 2008 to 2017: How Guidance Evolved
To understand what is changing now, it helps to see where guidance stood before. AASM published its oral appliance practice parameter in 2006-2008 and its surgical and combined-therapy updates in 2010 and 2017.
2008-era language
Mandibular advancement devices were positioned as alternatives for mild-to-moderate OSA when CPAP was rejected or not tolerated. Surgical options were reserved for selected anatomic indications. Nasal devices, including soft silicone stents, sat in the broader category of complementary therapies, with cautious wording about evidence quality.
2017-era language
The 2017 AASM/AADSM joint clinical practice guideline elevated oral appliances closer to CPAP as a first-line option for mild OSA when patient preference favored them. Positional therapy received clearer recognition. Nasal devices were still discussed mostly under primary snoring and adjunct use.
What changed in the 2020s evidence base
Between 2020 and 2026, more head-to-head trials, larger compliance datasets, and phenotype-driven analyses appeared. Real-world adherence data started to dominate, since efficacy without use is meaningless. Nasal devices benefited from this shift because adherence is consistently higher than CPAP.
Candidacy: Who Is the Best Fit Today
Modern AASM-style evidence appraisal is increasingly phenotype-driven. The question has moved from "which device is best on average" to "which device fits this patient's anatomy and preferences."
Strong fit for nasal stents
- AHI 5 to 15 (mild OSA) with primary nasal-collapse contribution.
- Supine-dominant event distribution.
- Strong patient preference against CPAP.
- Travel-heavy lifestyle where CPAP is impractical.
- CPAP intolerance after a fair trial.
Mixed or partial fit
- AHI 15 to 20 (lower moderate range) when used alongside positional therapy.
- Mild OSA with significant retrognathia, where mandibular devices may suit better.
- Pure mouth-breathing phenotype, where layered solutions are needed.
Weak fit
- Severe OSA (AHI over 30) without comorbidity-driven exception.
- Central sleep apnea predominantly.
- Significant fixed nasal obstruction requiring surgical correction first.
- Severe OSA: CPAP first.
- Moderate OSA without retrognathia: trial nasal stent or oral appliance, often layered.
- Mild OSA with nasal phenotype: nasal stent is now a credible first-line non-CPAP option.
- Primary snoring, no significant OSA: nasal stent is a strong first choice.
Nasal Stents vs Mandibular Devices in Current Guidance
The most useful comparison for patients is between the two main non-CPAP options: nasal stents and mandibular advancement devices.
| Aspect | Nasal stent | Mandibular advancement device |
|---|---|---|
| Mechanism | Maintains nasal airway patency | Pulls jaw and tongue forward |
| Best phenotype | Nasal collapse, mouth-prone snorers | Retrognathia, oropharyngeal collapse |
| Mean AHI reduction | 30-55% | 40-60% |
| Adherence | 65-80% | 50-65% |
| Cost (Europe) | 30-100 EUR | 500-2000 EUR custom |
| Side effects | Mild local irritation early on | Jaw soreness, bite changes long-term |
The honest current direction: neither is universally better. Choice should be phenotype-driven and patient-preference-driven. Some clinics are now offering both options and tracking which delivers better real-world results per patient.
Adjunct vs Primary Therapy: The Layered Approach
One of the clearest evolutions in current guidance is the layered approach. Rather than one device versus another, modern evidence-based sleep medicine increasingly stacks compatible therapies.
Layered options
- Nasal stent + positional therapy: Strong for supine-dominant mild-moderate OSA.
- Nasal stent + weight loss program: Effective when obesity is a major contributor.
- Nasal stent + sleep hygiene + alcohol reduction: Mid-range mild OSA, lifestyle component.
- Mandibular device + positional therapy: Retrognathia plus supine-dominance.
Why layering wins
Each therapy targets a different physiological axis. Combining therapies often delivers more total AHI reduction than the strongest single therapy, with better adherence than CPAP alone. We discuss this further in our positional therapy guide.
Patient Preference Data: A New Pillar in Guidance
Modern AASM-style appraisal increasingly weighs patient preference and shared decision-making, not just mean efficacy numbers. This represents a real shift from older guideline language.
Why preference matters in OSA
Sleep apnea therapy is used nightly for years. A device that the patient hates is unlikely to deliver real-world benefit, regardless of trial efficacy. Preference data, dropout reasons, and quality-of-life outcomes are now central to guideline appraisal.
What surveys consistently show
- Patients prefer non-mechanical, silent, travel-friendly therapies when efficacy is comparable.
- Mask discomfort and travel inconvenience are the top CPAP discontinuation drivers.
- Cost concerns lead many mild-OSA patients to abandon CPAP rentals.
- Nasal devices score well on portability, simplicity, and partner acceptability.
How guidelines are responding
Newer practice statements are explicitly recommending shared decision-making for mild OSA, where multiple options have similar efficacy curves but different lifestyle profiles. This opens more room for nasal stents and oral appliances as legitimate first choices.
Phenotype-Driven Sleep Medicine: The Underlying Shift
Behind the practical guideline changes lies a deeper scientific shift. Sleep medicine has moved from a single AHI-driven model to a multi-trait phenotype model. This affects how every therapy, including nasal stents, is positioned.
The four key OSA traits
- Anatomic compromise: upper airway collapsibility (Pcrit).
- Loop gain: ventilatory control instability.
- Arousal threshold: ease of wake-up during apneas.
- Muscle responsiveness: dilator muscle activation.
How this maps to therapy
Nasal stents target the anatomic axis specifically at the nasal pathway. Mandibular devices target oropharyngeal anatomy. CPAP is anatomy-agnostic and overrides all four traits. Newer drugs target loop gain or arousal threshold. The future of guideline language is to match each patient to the trait combination that fits.
- Ask your sleep physician about your phenotype, not just your AHI.
- Different phenotypes respond best to different therapies.
- Phenotype-driven choice often beats mean-efficacy thinking.
What Is Still Missing: Honest Limitations
Current AASM-style guidance has not fully formalized nasal stents as first-line therapy for mild OSA. There are good reasons for the cautious pace.
- Trial size. Most nasal-stent trials remain small. Larger multicenter studies are needed.
- Long-term outcomes. 12-month and 24-month adherence data are still maturing.
- Cardiovascular endpoint data. Long-horizon hard-endpoint trials with nasal devices do not yet exist at scale.
- Phenotype reproducibility. Different clinics use different phenotyping methods.
- Insurance integration. Coverage pathways for nasal stents are inconsistent across countries.
What Back2Sleep Users Say
Frequently Asked Questions
What is the AASM and why do its statements matter?
The American Academy of Sleep Medicine (AASM) is the leading professional body for sleep physicians in North America. Its position statements and clinical practice guidelines shape physician behavior, insurance coverage, and device adoption. AASM 2008 and 2017 oral appliance and surgical guidelines remain reference documents for OSA care worldwide.
Where do nasal stents fit in AASM guidance historically?
Historical AASM guidelines focused on CPAP, oral appliances, and surgery. Nasal stents and dilators sat in the alternative therapies section. The 2008 and 2017 guideline updates noted limited but supportive data for nasal devices in primary snoring and selected mild OSA. Newer evidence is steadily moving them into more formal consideration.
What does AASM 2026 evidence-based guidance suggest about candidacy?
Synthesizing the latest evidence, mild OSA (AHI 5-15) with primary nasal-collapse phenotype, supine-dominant events, and patient preference for non-mechanical therapy is the strongest candidacy profile. Patient adherence data, quality of life outcomes, and integration with positional therapy increasingly favor nasal devices in this band.
Are nasal stents now considered primary therapy for mild OSA?
Not officially in the same category as CPAP. The current direction in evidence-based sleep medicine is to consider nasal stents as a first-line option for mild OSA in selected phenotypes, alongside oral appliances and positional therapy. CPAP remains the standard of care for moderate-to-severe disease.
How do nasal stents compare to mandibular advancement devices in current guidance?
Mandibular advancement devices have a stronger published trial base, especially for moderate OSA. Nasal stents have higher real-world adherence and lower cost. Modern guidance increasingly recognizes that the best non-CPAP therapy depends on phenotype: mandibular for retrognathia, nasal for nasal-collapse, positional for supine-dominant.
Should this article be treated as the official AASM 2026 statement?
No. This article is an analysis of how AASM-style evidence-based guidance is evolving in 2026, based on cumulative published data and recent commentary. It is a synthesis, not a verbatim citation of a single official document. Always check the AASM website for the latest formal position statements before clinical decisions.
What does this mean for someone considering Back2Sleep?
If you have mild-to-moderate OSA confirmed by sleep testing, with a nasal-collapse component or strong preference for non-CPAP therapy, current evidence-based guidance increasingly supports trying a CE-certified nasal stent. Severe OSA still requires physician-supervised CPAP. Discuss results with a sleep physician and document outcomes objectively.
This article is informational only and does not replace medical advice. Always consult a qualified sleep physician before starting, stopping, or modifying any treatment for snoring or sleep apnea. Back2Sleep is a CE-certified Class I medical device intended for snoring and mild-to-moderate obstructive sleep apnea. Severe OSA cases require physician-supervised therapy.
Ready for quieter nights? Discover the Back2Sleep starter kit and find the right fit for you.
Not sure if you are at risk? Take our sleep risk screening to find out in just a few minutes.
Want to learn how it works? Explore the Back2Sleep nasal stent designed for comfortable, effective relief.
